Eurofins
A Synthetic DNA Process Development Scientist will lead the development, optimization, and scaling of chemical synthesis and purification processes for high-quality oligonucleotide production. This role involves troubleshooting synthesis challenges, collaborating with manufacturing and engineering teams, and ensuring compliance with quality systems in a GMP environment. The scientist will mentor lab technicians and author key technical documentation while evaluating new chemistries and technologies for production.
Headquarters
Luxembourg, Luxembourg, Luxembourg
Company Size
10001+ employees
Founded
1987
Eurofins Scientific is a global leader in laboratory testing and contract research, specializing in food, environmental, pharmaceutical product testing and agroscience CRO services. The group comprises more than 1,000 independent companies (over 950 laboratories) across 59 countries with over 65,000 staff and offers more than 200,000 analytical methods. Eurofins provides analytical testing, quality assurance and research services to support product safety, regulatory compliance and R&D. Clients choose Eurofins for its technical expertise, wide methodological coverage and extensive international laboratory network.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Eurofins.
14% below the average for this role
Senior Scientist, Oligo Chemistry
Leica Biosystems
Oligonucleotide Scientist II
SGA
Scientist II – Oligonucleotide Process Development, Manufacturing Development and Scale-Up
Abbott Laboratories
Senior Associate Scientist
Regeneron Pharmaceuticals
sgRNA Process Development Group
Intellia Therapeutics
Principal Scientist I or II, Oligonucleotide Chemistry and Innovation
Novartis